Abstract:PURPOSE OF REVIEW: The ability to generate pigs expressing a human complement regulatory protein (hCRP) and/or pigs in which the alpha1,3-galactosyltransferase gene has been knocked out (GT-KO) has largely overcome the barrier of hyperacute rejection of a pig organ transplanted into a primate. However, acute humoral xenograft rejection (AHXR), presenting as microvascular thrombosis and/or consumptive coagulopathy, remains a major hurdle to successful xenotransplantation. This review summarizes recent studies of the coagulation problems associated with xenotransplantation, and discusses potential strategies to overcome them.RECENT PROGRESS: Organ transplantation into nonhuman primates from GT-KO pigs that express a hCRP are not susceptible to hyperacute rejection. Nevertheless, most recipients of GT-KO and/or hCRP transgenic pig organs develop a consumptive coagulopathy, even when the graft remains functioning. This is associated with platelet aggregation, thrombocytopenia, anemia, and a tendency to bleed. Whilst this may reflect an ongoing immune response against the graft, (as exposure to anti-nonGal antibodies in vitro induces procoagulant changes in porcine ECs, even in the absence of complement), histological examination of the graft often shows only minimal features of immune injury, unlike grafts undergoing typical AHXR. Importantly, recent in vitro studies have indicated that the coincubation of porcine endothelial cells (ECs) with human platelets activates the platelets to express tissue factor, independent of a humoral immune response. These observations suggest that the use of organs from GT-KO pigs that express a hCRP may not be sufficient to prevent the development of a coagulation disorder following xenotransplantation, even if complete immunological tolerance can be achieved.SUMMARY: Both thrombotic microangiopathy and systemic consumptive coagulopathy are increasingly recognized as barriers to successful xenotransplantation. The breeding of transgenic pigs with one or more human anticoagulant genes, such as CD39 or tissue factor pathway inhibitor, is anticipated to inhibit the procoagulant changes that take place on the graft ECs, and thus may prevent or reduce platelet activation that arises as a result of immune-mediated injury. The identification of the molecular mechanisms that develop between porcine ECs and human platelets may allow pharmacological approaches to be determined that inhibit the development of thrombotic microangiopathy and consumptive coagulopathy. Hopefully, further genetic modification of the organ-source pigs, combined with systemic drug therapy to the recipient, will prolong graft survival further.

Pig BMSCs Transfected with Human TFPI Combat Species Incompatibility and Regulate the Human TF Pathway in Vitro and in a Rodent Model

Pig Bone Marrow Stromal Cells Transfected with Human Tissue Factor Pathway Inhibitor Combat Species Incompatibility and Regulate the Human TF Pathway in Vitro

Mutational analysis of pig tissue factor pathway inhibitor α to increase anti-coagulation activity in pig-to-human xenotransplantation

Studies on Coagulation Incompatibilities for Xenotransplantation

Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation

Pigs transgenic for human thrombomodulin have elevated production of activated protein C

Stable expression of the human thrombomodulin transgene in pig endothelial cells is associated with a reduction in the inflammatory response

Platelet aggregation and thrombosis in xenotransplantation between pigs and humans

Humanized von Willebrand factor reduces platelet sequestration in ex vivo and in vivo xenotransplant models

Molecular incompatibilities in hemostasis between swine and men--impact on xenografting

Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs

Progress towards overcoming coagulopathy and hemostatic dysfunction associated with xenotransplantation

Coagulation dysregulation as a barrier to xenotransplantation in the primate

Effects of human TFPI and CD47 expression and selectin and integrin inhibition during GalTKO.hCD46 pig lung perfusion with human blood

Porcine IL‐6, IL‐1β, and TNF‐α Regulate the Expression of Pro‐inflammatory‐related Genes and Tissue Factor in Human Umbilical Vein Endothelial Cells

Pig-to-baboon Heterotopic Heart Transplantation--exploratory Preliminary Experience with Pigs Transgenic for Human Thrombomodulin and Comparison of Three Costimulation Blockade-Based Regimens.

Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells

The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options

Modeling human anti-pig xenoimmune responses in a pig artery tissue grafted humanized mouse model

Sequence Alignment Analysis of Proteins Involved in Platelet-Endothelial Cell Interaction Identifies Molecular Incompatibilities Between Homo Sapiens and Sus Scrofa

Development of RAG2-/-IL2Rγ-/Y immune deficient FAH-knockout miniature pig